Endokrin 1
==NILAI PRETEST Pre-postest Endokrin 1
Section 1 Endocrinology 369 Approach to the Patient with Endocrine Disorders J. Larry Jameson The management of endocrine disorders requires a broad under standing of intermediary metabolism, reproductive physiology, bone metabolism, and growth. Accordingly, the practice of endocrinology is intimately linked to a conceptual framework for understanding hormone secretion, hormone action, and principles of feedback control (Chap. 370). The endocrine system is evaluated primarily by measuring hormone concentrations, arming the clinician with valuable diagnostic information. Most disorders of the endocrine system are amenable to effective treatment once the correct diagnosis is established. Endocrine deficiency disorders are treated with physiologic hormone replace ment; hormone excess conditions, which usually are caused by benign glandular adenomas, are managed by removing tumors surgically or reducing hormone levels medically. SCOPE OF ENDOCRINOLOGY The specialty of endocrinology encompasses the study of glands and the hormones they produce. The term endocrine was coined by Starling to contrast the actions of hormones secreted internally (endocrine) with those secreted externally (exocrine) or into a lumen, such as the gastrointestinal tract. The term hormone, derived from a Greek phrase meaning “to set in motion,” aptly describes the dynamic actions of hormones as they elicit cellular responses and regulate phys iologic processes through feedback mechanisms. Unlike many other specialties in medicine, it is not possible to define endocrinology strictly along anatomic lines. The classic endocrine glands—pituitary, thyroid, parathyroid, pancreatic islets, adrenals, and gonads—communicate broadly with other organs through the nervous system, hormones, cytokines, and growth factors. In addition to its tra ditional synaptic functions, the brain produces a vast array of peptide hormones, and this has led to the discipline of neuroendocrinology. Through the production of hypothalamic releasing factors, the central nervous system (CNS) exerts a major regulatory influence over pitu itary hormone secretion (Chap. 371). The peripheral nervous system stimulates the adrenal medulla. The immune and endocrine systems are also intimately intertwined. The adrenal hormone cortisol is a powerful immunosuppressant. Cytokines and interleukins (ILs) have profound effects on the functions of the pituitary, adrenal, thyroid, and gonads. Common endocrine diseases such as autoimmune thyroid disease and type 1 diabetes mellitus are caused by dysregulation of immune surveillance and tolerance. Less common diseases such as polyglandular failure, Addison’s disease, and lymphocytic hypophysi tis also have an immunologic basis. The interdigitation of endocrinology with physiologic processes in other specialties sometimes blurs the role of hormones. For example, hormones play an important role in maintenance of blood pressure, intravascular volume, and peripheral resistance in the cardiovascular system. Vasoactive substances such as catecholamines, angiotensin II, endothelin, and nitric oxide are involved in dynamic changes of vascu lar tone in addition to their multiple roles in other tissues. The heart is the principal source of atrial natriuretic peptide, which acts in classic endocrine fashion to induce natriuresis at a distant target organ (the kidney). Erythropoietin, a traditional circulating hormone, is made in the kidney and stimulates erythropoiesis in bone marrow (Chap. 59). The kidney is also integrally involved in the renin-angiotensin axis (Chap. 379) and is a primary target of several hormones, including parathyroid hormone (PTH), mineralocorticoids, and vasopressin. The gastrointestinal tract produces a vast array of peptide hormones, such as cholecystokinin, ghrelin, gastrin, secretin, and vasoactive intestinal peptide, among many others. Carcinoid and islet tumors can secrete excessive amounts of these hormones, leading to specific clinical syndromes (Chap. 80). Many of these gastrointestinal hormones are also produced in the CNS, where their functions are poorly under stood. Adipose tissue produces leptin, which acts centrally to control appetite, along with adiponectin, resistin, and other hormones that regulate metabolism. As hormones such as inhibin, ghrelin, and leptin are discovered, they become integrated into the science and practice of medicine on the basis of their functional roles rather than their tissues of origin. Characterization of hormone receptors frequently reveals unex pected relationships to factors in nonendocrine disciplines. The growth hormone (GH) and leptin receptors, for example, are members of the cytokine receptor family. The G protein–coupled receptors (GPCRs), which mediate the actions of many peptide hormones, are used in numerous physiologic processes, including vision, smell, and neurotransmission. PATHOLOGIC MECHANISMS OF ENDOCRINE DISEASE Endocrine diseases can be divided into three major types of conditions: (1) hormone excess, (2) hormone deficiency, and (3) hormone resistance (Table 369-1). ■CAUSES OF HORMONE EXCESS Syndromes of hormone excess can be caused by neoplastic growth of endocrine cells, autoimmune disorders, and excess hormone admin istration. Benign endocrine tumors, including parathyroid, pituitary, and adrenal adenomas, often retain the capacity to produce hormones, reflecting the fact that these tumors are relatively well differentiated. Many endocrine tumors exhibit subtle defects in their “set points” for feedback regulation. For example, in Cushing’s disease, impaired feed back inhibition of adrenocorticotropic hormone (ACTH) secretion is associated with autonomous function. However, the tumor cells are not completely resistant to feedback, as evidenced by ACTH suppression by higher doses of dexamethasone (e.g., high-dose dexamethasone test) (Chap. 379). Similar set point defects are also typical of parathyroid adenomas and autonomously functioning thyroid nodules. The molecular basis of some endocrine tumors, such as the multiple endocrine neoplasia (MEN) syndromes (MEN1, 2A, 2B), has provided important insights into tumorigenesis (Chap. 381). MEN1 is character ized primarily by the triad of parathyroid, pancreatic islet, and pituitary tumors. MEN2 predisposes to medullary thyroid carcinoma, pheo chromocytoma, and hyperparathyroidism. The MEN1 gene, located on chromosome 11q13, encodes a putative tumor-suppressor gene, menin. Analogous to the paradigm first described for retinoblastoma, the affected individual inherits a mutant copy of the MEN1 gene, and tumorigenesis ensues after a somatic “second hit” leads to loss of func tion of the normal MEN1 gene (through deletion or point mutations). In contrast to inactivation of a tumor-suppressor gene, as occurs in MEN1 and most other inherited cancer syndromes, MEN2 is caused by activating mutations in a single allele. In this case, activating mutations of the RET protooncogene, which encodes a receptor tyrosine kinase, leads to thyroid C cell hyperplasia in childhood before the develop ment of medullary thyroid carcinoma. Elucidation of this pathogenic mechanism has allowed early genetic screening for RET mutations in individuals at risk for MEN2, permitting identification of those who may benefit from prophylactic thyroidectomy and biochemical screen ing for pheochromocytoma and hyperparathyroidism. PART 12 Endocrinology and Metabolism 2650 TABLE 369-1 Causes of Endocrine Dysfunction TYPE OF ENDOCRINE DISORDER EXAMPLES Hyperfunction Neoplastic Benign Malignant Ectopic Multiple endocrine neoplasia (MEN) Autoimmune Iatrogenic Infectious/inflammatory Activating receptor mutations Pituitary adenomas, hyperparathyroidism, autonomous thyroid or adrenal nodules, pheochromocytoma Adrenal cancer, medullary thyroid cancer, carcinoid Ectopic ACTH, SIADH secretion MEN1, MEN2 Graves’ disease Cushing’s syndrome, hypoglycemia Subacute thyroiditis LH, TSH, Ca2+, PTH receptors, Gs α Hypofunction Autoimmune Iatrogenic Infectious/inflammatory Hormone mutations Enzyme defects Developmental defects Nutritional/vitamin deficiency Hemorrhage/infarction Hashimoto’s thyroiditis, type 1 diabetes mellitus, Addison’s disease, polyglandular failure Radiation-induced hypopituitarism, hypothyroidism, surgical Adrenal insufficiency, hypothalamic sarcoidosis GH, LHβ, FSHβ, vasopressin 21-Hydroxylase deficiency Kallmann’s syndrome, Turner’s syndrome, transcription factors Vitamin D deficiency, iodine deficiency Sheehan’s syndrome, adrenal insufficiency Hormone Resistance Receptor mutations Membrane Nuclear Signaling pathway mutations Postreceptor GH, vasopressin, LH, FSH, ACTH, GnRH, GHRH, PTH, leptin, Ca2+ AR, TR, VDR, ER, GR, PPARγ Albright’s hereditary osteodystrophy Type 2 diabetes mellitus, leptin resistance Abbreviations: ACTH, adrenocorticotropic hormone; AR, androgen receptor; ER, estrogen receptor; FSH, follicle-stimulating hormone; GHRH, growth hormone–releasing hormone; GnRH, gonadotropin-releasing hormone; GR, glucocorticoid receptor; LH, luteinizing hormone; PPAR, peroxisome proliferator activated receptor; PTH, parathyroid hormone; SIADH, syndrome of inappropriate antidiuretic hormone; TR, thyroid hormone receptor; TSH, thyroid-stimulating hormone; VDR, vitamin D receptor. Mutations that activate hormone receptor signaling have been identified in several GPCRs. For example, activating mutations of the luteinizing hormone (LH) receptor cause a dominantly transmitted form of male-limited precocious puberty, reflecting premature stimu lation of testosterone synthesis in Leydig cells (Chap. 384). Activating mutations in these GPCRs are located predominantly in the transmem brane domains and induce receptor coupling to Gs α even in the absence of hormone. Consequently, adenylate cyclase is activated, and cyclic adenosine monophosphate (AMP) levels increase in a manner that mimics hormone action. A similar phenomenon results from activating mutations in Gs α. When these mutations occur early in development, they cause McCune-Albright syndrome. When they occur only in somatotropes, the activating Gs α mutations cause GH-secreting tumors and acromegaly (Chap. 373). In autoimmune Graves’ disease, antibody interactions with the thy roid-stimulating hormone (TSH) receptor mimic TSH action, leading to hormone overproduction (Chap. 375). Analogous to the effects of activating mutations of the TSH receptor, these stimulating autoanti bodies induce conformational changes that release the receptor from a constrained state, thereby triggering receptor coupling to G proteins. ■CAUSES OF HORMONE DEFICIENCY Most examples of hormone deficiency states can be attributed to glan dular destruction caused by autoimmunity, surgery, infection, inflam mation, infarction, hemorrhage, or tumor infiltration (Table 369-1). Autoimmune damage to the thyroid gland (Hashimoto’s thyroiditis) and pancreatic islet β cells (type 1 diabetes mellitus) is a prevalent cause of endocrine disease. Mutations in a number of hormones, hor mone receptors, transcription factors, enzymes, and channels can also lead to hormone deficiencies. ■HORMONE RESISTANCE Most severe hormone resistance syndromes are due to inherited defects in membrane receptors, nuclear receptors, or the pathways that transduce receptor signals. These disorders are characterized by defective hormone action despite the presence of increased hormone levels. In complete androgen resistance, for example, mutations in the androgen receptor result in a female phenotypic appearance in genetic (XY) males, even though LH and testosterone levels are increased (Chap. 381). In addition to these relatively rare genetic disorders, more common acquired forms of functional hormone resistance include insu lin resistance in type 2 diabetes mellitus, leptin resistance in obesity, and GH resistance in catabolic states. The pathogenesis of functional resistance involves receptor downregulation and postreceptor desen sitization of signaling pathways; functional forms of resistance are generally reversible. ■CLINICAL EVALUATION OF ENDOCRINE DISORDERS Because most glands are relatively inaccessible, the physical exami nation usually focuses on the manifestations of hormone excess or deficiency as well as direct examination of palpable glands, such as the thyroid and gonads. For these reasons, it is important to evaluate patients in the context of their presenting symptoms, review of systems, family and social history, and exposure to medications that may affect the endocrine system. Astute clinical skills are required to detect subtle symptoms and signs suggestive of underlying endocrine disease. For example, a patient with Cushing’s syndrome may manifest specific findings, such as central fat redistribution, skin striae, and proximal muscle weakness, in addition to features seen commonly in the general population, such as obesity, plethora, hypertension, and glucose intol erance. Similarly, the insidious onset of hypothyroidism—with mental slowing, fatigue, dry skin, and other features—can be difficult to dis tinguish from similar, nonspecific findings in the general population. Clinical judgment that is based on knowledge of disease prevalence and pathophysiology is required to decide when to embark on more extensive evaluation of these disorders. Laboratory testing plays an essential role in endocrinology by allowing quantitative assessment of hormone levels and dynamics. Radiologic imaging tests such as CHAPTER 369 Approach to the Patient with Endocrine Disorders 2651 computed tomography (CT) scan, magnetic resonance imaging (MRI), thyroid scan, and ultrasound are also used for the diagnosis of endo crine disorders. However, these tests generally are employed only after a hormonal abnormality has been established by biochemical testing. ■HORMONE MEASUREMENTS AND ENDOCRINE TESTING Immunoassays are the most important diagnostic tool in endocrinol ogy, as they allow sensitive, specific, and quantitative determination of steady-state and dynamic changes in hormone concentrations. Immunoassays use antibodies to detect specific hormones. For many peptide hormones, these measurements are now configured to use two different antibodies to increase binding affinity and specificity. There are many variations of these assays; a common format involves using one antibody to capture the antigen (hormone) onto an immo bilized surface and a second antibody, coupled to a chemiluminescent (immunochemiluminescent assay [ICMA]) or radioactive (immunora diometric assay [IRMA]) signal, to detect the antigen. These assays are sensitive enough to detect plasma hormone concentrations in the pico molar to nanomolar range, and they can readily distinguish structur ally related proteins, such as PTH from PTH-related peptide (PTHrP). A variety of other techniques are used to measure specific hormones, including mass spectroscopy, various forms of chromatography, and enzymatic methods; bioassays are now used rarely. Most hormone measurements are based on plasma or serum sam ples. However, urinary hormone determinations remain useful for the evaluation of some conditions. Urinary collections over 24 h provide an integrated assessment of the production of a hormone or metab olite, many of which vary during the day. It is important to ensure complete collections of 24-h urine samples; simultaneous measure ment of creatinine provides an internal control for the adequacy of collection and can be used to normalize some hormone measurements. A 24-h urine-free cortisol measurement largely reflects the amount of unbound cortisol, thus providing a reasonable index of biologi cally available hormone. Other commonly used urine determinations include 17-hydroxycorticosteroids, 17-ketosteroids, vanillylmandelic acid, metanephrine, catecholamines, 5-hydroxyindoleacetic acid, and calcium. The value of quantitative hormone measurements lies in their cor rect interpretation in a clinical context. The normal range for most hor mones is relatively broad, often varying by a factor of two- to tenfold. The normal ranges for many hormones are sex- and age-specific. Thus, using the correct normative database is an essential part of interpreting hormone tests. The pulsatile nature of hormones and factors that can affect their secretion, such as sleep, meals, and medications, must also be considered. Cortisol values increase fivefold between midnight and dawn; reproductive hormone levels vary dramatically during the female menstrual cycle. For many endocrine systems, much information can be gained from basal hormone testing, particularly when different components of an endocrine axis are assessed simultaneously. For example, low testos terone and elevated LH levels suggest a primary gonadal problem, whereas a hypothalamic-pituitary disorder is likely if both LH and testosterone are low. Because TSH is a sensitive indicator of thyroid function, it is generally recommended as a first-line test for thyroid disorders. An elevated TSH level is almost always the result of primary hypothyroidism, whereas a low TSH is most often caused by thyrotox icosis. These predictions can be confirmed by determining the free thy roxine level. In the less common circumstance when free thyroxine and TSH are both low, it is important to consider secondary hypopituitar ism caused by hypothalamic-pituitary disease. Elevated calcium and PTH levels suggest hyperparathyroidism, whereas PTH is suppressed in hypercalcemia caused by malignancy or granulomatous diseases. A suppressed ACTH in the setting of hypercortisolemia, or increased urine-free cortisol, is seen with hyperfunctioning adrenal adenomas. It is not uncommon, however, for baseline hormone levels associ ated with pathologic endocrine conditions to overlap with the normal range. In this circumstance, dynamic testing is useful to separate the two groups further. There are a multitude of dynamic endocrine tests, but all are based on principles of feedback regulation, and most responses can be rationalized based on principles that govern the reg ulation of endocrine axes. Suppression tests are used in the setting of suspected endocrine hyperfunction. An example is the dexamethasone suppression test used to evaluate Cushing’s syndrome (Chaps. 373 and 379). Stimulation tests generally are used to assess endocrine hypo function. The ACTH stimulation test, for example, is used to assess the adrenal gland response in patients with suspected adrenal insuf ficiency. Other stimulation tests use hypothalamic-releasing factors such as corticotropin-releasing hormone (CRH) and growth hormone releasing hormone (GHRH) to evaluate pituitary hormone reserve (Chap. 373). Insulin-induced hypoglycemia evokes pituitary ACTH and GH responses. Stimulation tests based on reduction or inhibition of endogenous hormones are now used infrequently. Examples include metyrapone inhibition of cortisol synthesis and clomiphene inhibition of estrogen feedback. ■SCREENING AND ASSESSMENT OF COMMON ENDOCRINE DISORDERS Many endocrine disorders are prevalent in the adult population (Table 369-2) and can be diagnosed and managed by general internists, TABLE 369-2 Examples of Prevalent Endocrine and Metabolic Disorders in the Adult DISORDER APPROX. PREVALENCE IN ADULTSa SCREENING/TESTING RECOMMENDATIONSb CHAPTER(S) Obesity 36% BMI ≥30 70% BMI ≥25 Calculate BMI Measure waist circumference Exclude secondary causes Consider comorbid complications 395 Type 2 diabetes mellitus >8% Beginning at age 45, screen every 3 years, or earlier in high-risk groups: FPG >126 mg/dL Random plasma glucose >200 mg/dL An elevated HbA1C Consider comorbid complications 396 Hyperlipidemia 20–25% Cholesterol screening at least every 5 years; more often in high-risk groups Lipoprotein analysis (LDL, HDL) for increased cholesterol, CAD, diabetes Consider secondary causes 400 (Continued) PART 12 Endocrinology and Metabolism 2652 family practitioners, or other primary health care providers. The high prevalence and clinical impact of certain endocrine diseases justi fies vigilance for features of these disorders during routine physical examinations; laboratory screening is indicated in selected high-risk populations. ■FURTHER READING G!l#% SH et al: Health disparities in endocrine disorders: Biological, clinical, and nonclinical factors—an Endocrine Society Scientific Statement. J Clin Endocrinol Metab 97:E1579, 2012. J&'G)!!* LJ (eds): Endocrinology: Adult and Pediatric, 7th ed. Philadelphia, Elsevier, 2016. L!)+&,- DL: A Biographical History of Endocrinology. Hoboken, Wiley Blackwell, 2016. M# S, P!l!%(./ KS, L&)(%0$)1 HM (eds): Williams Textbook of Endocrinology, 13th ed. Philadelphia, Elsevier, 2016
Alur Sesi: 01 Pretest → 02 MATERI (AKTIF) → 03 POSTTEST
Broty: "Materi selesai dibaca. Lanjutkan ke posttest untuk mengevaluasi pemahamanmu pada sesi ini."
- Langkah Selanjutnya: Lanjut ke Posttest Sesi 1 →
- Navigasi Blok: Daftar Sesi Endokrin · Beranda